Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) announced the appointment of Eilon Elmalem as site head of its wholly owned subsidiary Scinai Biopharma Services’ Yavne CDMO facility, effective June 14, 2026. Elmalem, who has supported the company as an external consultant for the past two years, brings more than two decades of biotechnology and pharmaceutical operations experience and will oversee site operations and engineering activities as Scinai continues expanding its contract development and manufacturing platform.
The appointment underscores Scinai's strategic focus on bolstering its CDMO capabilities, which are critical to its growth strategy. The Yavne facility is a key asset for Scinai Biopharma Services, providing development and manufacturing services to biotechnology and pharmaceutical companies. With Elmalem's leadership, the company aims to enhance operational efficiency and capacity to meet increasing demand for contract manufacturing services.
Eilon Elmalem's extensive background includes senior roles in biotech and pharma operations, where he has managed complex facilities and led engineering projects. His previous consulting work with Scinai gives him deep familiarity with the company's operations and strategic goals. This continuity is expected to facilitate a smooth transition and accelerate progress on ongoing expansion initiatives.
The move comes as Scinai Immunotherapeutics continues to advance its pipeline of innovative immunology therapies, licensed from the Max Planck Society and PinCell S.r.l. The CDMO business provides a revenue stream that supports the development of these therapies, while also offering services to external clients. By strengthening the leadership at the Yavne facility, Scinai positions itself to capture more opportunities in the growing CDMO market.
For more details on the announcement, visit https://ibn.fm/VLt3w.
